Ledipasvir (formerly GS-5885), Treatment of chronic Hepatitis C infection
Ledipasvir nonproprietary drug name
http://www.ama-assn.org/resources/doc/usan/ledipasvir.pdf
November 28, 2012. N12/139. STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL. USAN ZZ-132. LEDIPASVIR.
MOLECULAR FORMULA C49H54F2N8O6
MOLECULAR WEIGHT 889
Gilead Sciences
CODE DESIGNATION GS-5885
CAS REGISTRY NUMBER 1256388-51-8
Ledipasvir (formerly GS-5885) is an experimental drug for the treatment of hepatitis C being developed by Gilead Sciences.[1] It is currently in Phase III clinical trials.[2] It is being studied in combination with other direct-acting antiviral agents that interfere with HCV replication.
Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein.
Ledipasvir is being tested in interferon-free regimens with other direct-acting antiviral agents for hepatitis C.
Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the HCV protease inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1.[3][4] Gilead is developing a sofosbuvir + ledipasvir coformulation that is being tested with and without ribavirin.
- “Ledipasvir”. United States Adopted Name.
- “GS-5885”. Gilead Sciences.
- ELECTRON: 100% Suppression of Viral Load through 4 Weeks’ Post-treatment for Sofosbuvir + Ledipasvir (GS-5885) + Ribavirin for 12 Weeks in Treatment-naïve and -experienced Hepatitis C Virus GT 1 Patients. Gane, Edward et al. 20th Conference on Retroviruses and Opportunistic Infections. March 3–6, 2013. Abstract 41LB.
- CROI 2013: Sofosbuvir + Ledipasvir + Ribavirin Combo for HCV Produces 100% Sustained Response. Highleyman, Liz. HIVandHepatitis.com. 4 March 2013.
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

Reblogged this on Med.Chem.in.Iceland.
LikeLike
Reblogged this on GREEN MED CHEMISTRY.
LikeLike
Reblogged this on Organic Reactions in Medchem.
LikeLike
Reblogged this on MedCheminAustralia.
LikeLike
Reblogged this on Srilanka-Chem.
LikeLike
Reblogged this on Srilanka-Chem.
LikeLike
Reblogged this on Med.Chem in Nepal.
LikeLike
Reblogged this on My Blog on Medicinal Chemistry.
LikeLike
Reblogged this on SreetamaDutt's MedMicro Blog.
LikeLike